Previous 10 | Next 10 |
SEATTLE, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today provided a business update and reported financial results for the q...
Shares of Chinook Therapeutics have reacted well recently to a surprising secondary offering conducted at $14.00, providing it with additional capital for the commercialization of atrasentan. Although only one (likely) inferior therapy has been approved for the company’s initia...
SEATTLE, July 05, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that Chinook management is scheduled to participate in a ...
Chinook Therapeutics ( NASDAQ: KDNY ) on Tuesday said it had got European orphan drug designation for its BION-1301 treatment for primary IgA nephropathy, a type of kidney disease. The European drug regulator's orphan designation is given to medicines developed for...
SEATTLE, July 05, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced the European Commission has granted orphan drug designati...
=Gainers: BlackSky Technology (BKSY) +93%. StoneMor (STON) +51%. Genocea Biosciences (GNCA) +35%. Hoegh LNG Partners (HMLP) +31%. Caleres (CAL) +27%. Evelo Biosciences (EVLO) +20%. Spire Global (SPIR) +17%. Groupon (GRPN) +17%. Abercrombie & Fitch (ANF) +17%. Losers: Verrica Pharmaceutica...
Kim Kardashian's influence played a role in Wednesday's midday trading, lifting shares of Beyond Meat (NASDAQ:BYND), which climbed on news of an endorsement deal with celebrity influencer Kim Kardashian. In other news, Scotiabank (BNS) and Autohome (ATHM) both rose on the release of their res...
Chinook Therapeutics (NASDAQ:KDNY) shares have slid 7% pre-market after the biopharmaceutical company priced its $105M share and warrant offering. The offering consists of 6,428,572 shares of common stock priced at $14/share. Underwriters will have a 30-day option to purchase up to ...
SEATTLE, May 24, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY) today announced the pricing of its underwritten public offering of 6,428,572 shares of its common stock at a price to the public of $14.00 per share. In addition, and in lieu of common stock, Chinook is offe...
Biopharmaceutical company Chinook Therapeutics (NASDAQ:KDNY) commenced an underwritten public offering of its common stock. In lieu of common stock, the company will also offer and sell to certain investors pre-funded warrants to purchase shares. KDNY intends to grant the underwriters a 30-da...
News, Short Squeeze, Breakout and More Instantly...
Chinook Therapeutics Inc Com Company Name:
KDNY Stock Symbol:
NASDAQ Market:
Chinook Therapeutics Inc Com Website:
Chinook Therapeutics, Inc. (NASDAQ: KDNY) has caught the attention of the investment community today with its bullish price action. The company's shares are currently up 2.86% on the day to $40.3. Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, dev...
SEATTLE, July 28, 2023 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that the first patient with IgA nephropathy (IgAN) has been enr...
NEW YORK, NY / ACCESSWIRE / July 27, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Sculptor Capital Management Inc. (NYS...